Search

Your search keyword '"Yan-xia Xing"' showing total 2 results
Start Over Author "Yan-xia Xing" Search Limiters Full Text
2 results on '"Yan-xia Xing"'

1. The Potential Role of Extracellular Vesicles in COVID-19 Treatment: Opportunity and Challenge

Author

Yan-yan Yan, Wen-min Zhou, Yu-qing Wang, Qiao-ru Guo, Fu-xi Zhao, Zhuang-yan Zhu, Yan-xia Xing, Hai-yan Zhang, Mohamad Aljofan, Alireza Mosavi Jarrahi, Bolat Makabel, and Jian-ye Zhang

Subjects
COVID-19, SARS-CoV-2, extracellular vesicles (EVs), mesenchymal stem cell (MSC), immunomodulation, ACE2, Biology (General), QH301-705.5
Abstract

SARS-CoV-2 infection has become an urgent public health concern worldwide, severely affecting our society and economy due to the long incubation time and high prevalence. People spare no effort on the rapid development of vaccine and treatment all over the world. Amongst the numerous ways of tackling this pandemic, some approaches using extracellular vesicles (EVs) are emerging. In this review, we summarize current prevalence and pathogenesis of COVID-19, involving the combination of SARS-CoV-2 and virus receptor ACE2, endothelial dysfunction and micro thrombosis, together with cytokine storm. We also discuss the ongoing EVs-based strategies for the treatment of COVID-19, including mesenchymal stem cell (MSC)-EVs, drug-EVs, vaccine-EVs, platelet-EVs, and others. This manuscript provides the foundation for the development of targeted drugs and vaccines for SARS-CoV-2 infections.

Published
2021
Full Text
View/download PDF

2. Effect of DC-CIK treatment on tumor markers and T cell subsets in patients with advanced ovarian cancer

Author

Jie-Qun Guo, Yan-Xia Xing, Fu-Juan Li, Yan-Li Yang, and Yong-Lan Hou

Subjects
Ovarian cancer, DC-CIK, T lymphocyte subsets, lcsh:R, lcsh:Medicine, Tumor marker
Abstract

Objective: To investigate the effects of dendritic cells (DC) and cytokine induced killer cells (CIK) on tumor markers and T cell subsets in peripheral blood of patients with advanced ovarian cancer. Methods: A total of 100 cases of patients with advanced ovarian cancer who were proved by operation and pathology in the department of gynecologic oncology in our hospital were selected from April 2013 to April 20l6, and randomly divided into experimental group and control group, the control group was treated with TC (Taxinol+Cisplat) chemotherapy alone, the experimental group was treated with DC-CIK combined with chemotherapy. Before and after treatment, the changes of CD3+, CD4+, CD8+, CD4+/CD8+, CD4+/CD25+, NK cells in peripheral blood and serum tumor markers (CA125, CA19-9, HE4) were detected. Results: Before treatment, the phenotypes of T cell subsets in the two groups were not significantly different; in the experimental group after treatment, the levels of CD3+, CD4+, CD4+/CD8+, and NK cells were increased,while the levels of CD4+/CD25+ and CD8+ were decreased, compared with before treatment, the differences were statistically significant; the phenotype changes of T cells were not statistically significant before and after treatment in the control group; after treatment, there were significant differences in the levels of CD4+, CD8+, CD4+/CD8+, CD4+/CD25+ and NK cells between the two groups. Before treatment, there were no significant differences in HE4 value, CA125 value and CA19-9 value between the two groups; after treatment, the tumor markers in the two groups were all decreased, and the difference was significant as compared with those before treatment; after treatment, the CA125 value, CA19-9 value and HE4 value were (73.68±79.46) U/mL, (54.32±32.85) U/mL and (69.57±39.85) pmol/L respectively, the values of three tumor markers were compared with the control group, with a statistical difference. Conclusion: DC-CIK treatment can improve the immune ability and antitumor activity of T lymphocytes in patients with advanced ovarian cancer.

Published
2016

Catalog

Books, media, physical & digital resources
See catalog results